Discuss whether GLP-1 therapy is appropriate for concurrent diabetes or obesity, potential drug interactions with DMARDs, realistic expectations about anti-inflammatory effects, and coordination between your rheumatology and endocrinology care teams
Matis has been involved in translational research, helping bridge the gap between scientific discovery and patient care
Beyond hormonal changes, several interconnected factors may contribute to perimenopausal weight gain: Metabolic slowdown : Basal metabolic rate naturally decreases with age, meaning the body burns fewer calories at rest Muscle mass loss : Sarcopenia (age-related muscle loss) accelerates during perimenopause, further reducing metabolic rate Sleep disruption : Night sweats and insomnia, common perimenopausal symptoms, interfere with hormones regulating appetite and glucose metabolism Mood changes : Anxiety, depression, and stress during this transition may lead to emotional eating patterns Reduced physical activity : Fatigue, joint pain, and other symptoms may decrease exercise tolerance Research suggests women may gain weight gradually during perimenopause, though individual experiences vary considerably
( [Google Scholar] 30.Kerver GA, Engel SG, Gunstad J, Crosby RD, Steffen KJ
How GLP-1 pharmacokinetics shape your timing decision Understanding why timing matters requires understanding how these medications move through your body
o , Application of GLP-1 and GLP-1MK-801 induced changes in fluorescence indicative of rises in intracellular calcium (%F/F 0 ) as shown by these representative fluorescent responses of two different Fura 2-AM loaded cells to application of GLP-1 (1 M) or GLP-1MK-801 (1 M)
